Document Detail


The acute coronary ischemic syndromes--the central role of thrombosis.
MedLine Citation:
PMID:  9191478     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The postulate that thrombotic coronary occlusion was the underlying pathophysiologic event in the acute coronary ischemic syndromes was developed over the years 1912-60. This concept prompted the development of anticoagulant and thrombolytic therapies and the use of acetylsalicylic acid in such patients. A central role for coronary thrombus came to be questioned in the 1970s and the use of anticoagulants dramatically decreased and thrombolytic therapy was little used. Coronary angiographic studies among patients during the early hours of evolving myocardial infarction re-established the etiologic role of coronary thrombosis in the acute coronary ischemic syndromes, and were supplemented by careful autopsy studies. The concepts of meta-analysis lead to more accurate interpretations of earlier randomized, controlled trials of anticoagulant, antiplatelet and thrombolytic therapies. Large clinical trials have provided confirmatory evidence and have established the benefits of antiplatelet and thrombolytic agents in the acute ischemic syndromes. The benefit of long term anticoagulation following myocardial infarction has been demonstrated, although the benefit during the acute in-hospital phase of myocardial infarction is still uncertain. Currently, clinical trials are evaluating new antithrombins, antiplatelet agents, and thrombolytic agents and regimens among patients with unstable angina, acute myocardial infarction, and undergoing angioplasty for complex coronary lesions.
Authors:
J A Cairns
Related Documents :
2003658 - Elapsed time from symptom onset and acute myocardial infarction in a community hospital.
3961468 - Intracoronary thrombolytic therapy performed within a coronary care unit: one year's ex...
19605778 - The tissue-type plasminogen activator story.
2930908 - The surgeon's role in the treatment of acute myocardial infarction.
8203318 - Management of chronic ventricular arrhythmias.
12713448 - Enalaprilat, losartan and lu 135252 in coronary blood flow regulation.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The Canadian journal of cardiology     Volume:  12     ISSN:  0828-282X     ISO Abbreviation:  Can J Cardiol     Publication Date:  1996 Oct 
Date Detail:
Created Date:  1997-07-07     Completed Date:  1997-07-07     Revised Date:  2008-04-09    
Medline Journal Info:
Nlm Unique ID:  8510280     Medline TA:  Can J Cardiol     Country:  CANADA    
Other Details:
Languages:  eng     Pagination:  901-7     Citation Subset:  IM    
Affiliation:
Department of Medicine, McMaster University, Hamilton, Ontario.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticoagulants / therapeutic use
Coronary Thrombosis / complications*,  drug therapy
Humans
Myocardial Ischemia / etiology*
Platelet Aggregation Inhibitors / therapeutic use
Thrombolytic Therapy
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Platelet Aggregation Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Interventions for coronary stenosis--a Canadian experience of 30 revolutionary years.
Next Document:  Evolution of the CCU from rhythm, function and protection to reperfusion and beyond: a personal jour...